PRME stock forecast, quote, news & analysis
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression... Show more
Why Prime Medicine (PRME) Stock Is Down -14% in the Last 30 Days
Key Takeaways
- Prime Medicine (PRME) shares fell roughly 14% over the trailing 30 days, from a close of $3.58 on August 26, 2026 to $3.07 on September 24, 2026.
- The decline occurred despite a steady stream of pipeline milestones, underscoring ongoing volatility and selling pressure across the gene-editing sector.
- After the September 24 close, the U.S. FDA cleared the investigational new drug (IND) application for PM647, Prime Medicine's Alpha-1 Antitrypsin Deficiency (AATD) program, sending shares up about 13% in after-hours trading.
- Over the trailing quarter, the stock is down roughly 10.5% after peaking near $4.62 in early July, reflecting a broader pullback from mid-2026 highs.
- Investors continue to weigh the company's advancing clinical pipeline against its cash runway, which management projects will fund operations into 2027.
Prime Medicine (PRME) Company Overview and Market Position
Prime Medicine, Inc. is a Cambridge, Massachusetts-based biotechnology company focused on developing next-generation genetic medicines using its proprietary Prime Editing platform. Prime Editing is a versatile gene-editing technology designed to "search and replace" DNA sequences with precision while minimizing unwanted modifications, potentially correcting nearly all types of genetic mutations without introducing double-stranded DNA breaks.
The company's pipeline centers on three core areas: liver, lung, and immunology and oncology. Its lead wholly owned programs include PM577a for Wilson Disease and PM647 for Alpha-1 Antitrypsin Deficiency, both designed for in vivo delivery to the liver. Prime Medicine is also advancing an ex vivo program, PM359, for Chronic Granulomatous Disease (CGD), as well as a Cystic Fibrosis effort supported by the Cystic Fibrosis Foundation and Prime Edited CAR-T research in partnership with Bristol Myers Squibb. Investors follow PRME for its differentiated platform and its potential to address diseases with limited curative treatment options.
Prime Medicine (PRME) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PRME declined from a closing price of $3.58 on August 26, 2026 to $3.07 on September 24, 2026, a drop of approximately 14.2%. The move was not a straight line: the stock rebounded to $3.54 on September 22 before giving back those gains and closing near the period low.
The quarterly picture tells a similar story of pressure after a mid-year peak. From a late-June close of $3.43, PRME is down roughly 10.5% through September 24. Notably, the stock rallied to a closing high of $4.62 on July 8, 2026, before a sustained pullback carried shares back below $3.10. The result has been a lower-high, lower-low pattern over the trailing three months, with the stock trading in a broad $2.90 to $4.60 range.
What Drove PRME Stock Price in the Last 30 Days
The 30-day decline in PRME appears tied primarily to sector-wide volatility rather than a single company-specific negative. Prime Medicine's peer group in gene editing experienced notable swings during the period, with names such as CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Beam Therapeutics (BEAM), and Editas Medicine (EDIT) also trading lower, reflecting a risk-off tone across speculative, pre-revenue biotech.
Within the period, PRME experienced sharp two-way moves. After a double-digit bounce on September 22, shares gave back the advance over the following sessions. Profit-taking and ongoing concerns about cash burn likely contributed, given the company's cash, cash equivalents, and investments stood at $108.8 million as of June 30, 2026, with a runway guided into 2027.
The most significant company-specific catalyst arrived after the close on September 24, 2026, when Prime Medicine announced that the FDA had cleared the IND for PM647, allowing clinical studies in the U.S. for AATD. The news lifted shares about 13% in after-hours trading, but because it occurred after the regular session, it was not yet reflected in the $3.07 close used in the 30-day calculation.
What Drove PRME Stock Performance Over the Last Quarter
Over the trailing quarter, PRME's trajectory was shaped by a shift from mid-summer optimism to a more cautious posture. The early-July run toward $4.62 reflected enthusiasm around the company's advancing liver franchise, including progress on its Wilson Disease program and anticipation of regulatory filings. In its second-quarter 2026 results reported in August, Prime Medicine posted a net loss of $42.1 million, narrower than the $52.6 million loss a year earlier, and reiterated cash runway into 2027.
However, the rally proved difficult to sustain. As the broader biotech complex faced rotation away from high-risk, cash-consuming names, PRME gave back a substantial portion of its gains. Management's strategic focus on the in vivo liver franchise, deprioritization of the CGD program, and the reduced workforce from the May 2025 restructuring have lowered operating expenses, but the company remains pre-revenue, leaving the share price sensitive to sentiment around financing and clinical timelines.
Trending AI Robots
For traders seeking a data-driven approach to volatile names like Prime Medicine, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are highlighted in this section. These bots vary widely in strategy, timeframe, and performance metrics, giving users a range of approaches to evaluate rather than a one-size-fits-all signal. For those interested in supplementing their own analysis with algorithmic tools, exploring the Trending AI Robots selection can offer additional perspective on how automated systems are positioning across the market.
PRME Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several milestones are likely to influence PRME. Prime Medicine expects initial clinical data from its Wilson Disease program (PM577a) and AATD program (PM647) in 2027, following the September 2026 FDA clearance of the PM647 IND. The company also plans to submit a Biologics License Application for PM359 in the first half of 2027, supported by FDA designations including RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease.
Key risks to monitor include clinical trial outcomes, the pace of patient enrollment, regulatory decisions, and the company's cash position, which may require additional financing and could dilute existing shareholders. Broader factors such as interest-rate expectations, risk appetite for pre-revenue biotech, and sector rotation will also play a role. Market data indicates a consensus "Buy" rating among analysts covering PRME, with an average price target well above recent trading levels, though such targets are inherently uncertain for clinical-stage companies. As with any speculative biotech investment, outcomes will hinge heavily on execution across the pipeline.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PRME in downward trend: price dove below 50-day moving average on September 23, 2026
PRME moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 30 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRME as a result. In 54 of 64 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for PRME turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 30 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
The 10-day moving average for PRME crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 51 cases where PRME's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +13.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRME advanced for three days, in 157 of 192 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
PRME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 80 of 104 cases where PRME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.261) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. PRME’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology